These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 14986282)

  • 1. Liver injury during highly active antiretroviral therapy: the effect of hepatitis C coinfection.
    Bonacini M
    Clin Infect Dis; 2004 Mar; 38 Suppl 2():S104-8. PubMed ID: 14986282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection.
    Aranzabal L; Casado JL; Moya J; Quereda C; Diz S; Moreno A; Moreno L; Antela A; Perez-Elias MJ; Dronda F; Marín A; Hernandez-Ranz F; Moreno A; Moreno S
    Clin Infect Dis; 2005 Feb; 40(4):588-93. PubMed ID: 15712082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of coinfection with hepatitis C virus on morbidity and mortality due to human immunodeficiency virus infection in the era of highly active antiretroviral therapy.
    Tedaldi EM; Baker RK; Moorman AC; Alzola CF; Furhrer J; McCabe RE; Wood KC; Holmberg SD;
    Clin Infect Dis; 2003 Feb; 36(3):363-7. PubMed ID: 12539079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-related liver disease: ARV drugs, coinfection, and other risk factors.
    Puoti M; Nasta P; Gatti F; Matti A; Prestini K; Biasi L; Carosi G
    J Int Assoc Physicians AIDS Care (Chic); 2009; 8(1):30-42. PubMed ID: 19211929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low incidence of severe liver events in HIV patients with and without hepatitis C or B coinfection receiving lopinavir/ritonavir.
    Palacios R; Vergara S; Rivero A; Aguilar I; Macías J; Camacho A; Lozano F; García-Lázaro M; Pineda JA; Torre-Cisneros J; Márquez M; Santos J
    HIV Clin Trials; 2006; 7(6):319-23. PubMed ID: 17197379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV and hepatitis C co-infection: the role of HAART in HIV/hepatitis C virus management.
    Jones M; Núñez M
    Curr Opin HIV AIDS; 2011 Nov; 6(6):546-52. PubMed ID: 22001896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute liver enzyme elevations in HIV-1-infected patients.
    Livry C; Binquet C; Sgro C; Froidure M; Duong M; Buisson M; Grappin M; Quantin C; Portier H; Chavanet P; Piroth L
    HIV Clin Trials; 2003; 4(6):400-10. PubMed ID: 14628283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort.
    Torti C; Lapadula G; Casari S; Puoti M; Nelson M; Quiros-Roldan E; Bella D; Pastore G; Ladisa N; Minoli L; Sotgiu G; Mazzotta F; Lo Caputo S; Di Perri G; Filice G; Tinelli C; Carosi G;
    BMC Infect Dis; 2005 Jul; 5():58. PubMed ID: 16018804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Highly active antiretroviral therapy-related hepatotoxicity in human immunodeficiency virus and hepatitis C virus co-infected patients with advanced liver fibrosis in Taiwan.
    Chou CC; Tsai HC; Wu KS; Sy CL; Chen JK; Chen YS; Lee SS
    J Microbiol Immunol Infect; 2016 Aug; 49(4):546-53. PubMed ID: 25440980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Managing symptomatic drug-induced liver injury in HIV-hepatitis C virus-coinfected patients: a role for interferon.
    McGovern BH; Birch C; Zaman MT; Bica I; Stone D; Quirk JR; Davis B; Zachary K; Basgoz N; Graeme-Cook F; Gandhi RT
    Clin Infect Dis; 2007 Nov; 45(10):1386-92. PubMed ID: 17968840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV and hepatitis C coinfection.
    Matthews GV; Dore GJ
    J Gastroenterol Hepatol; 2008 Jul; 23(7 Pt 1):1000-8. PubMed ID: 18707597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV infection and hepatic enzyme abnormalities: intricacies of the pathogenic mechanisms.
    Pol S; Lebray P; Vallet-Pichard A
    Clin Infect Dis; 2004 Mar; 38 Suppl 2():S65-72. PubMed ID: 14986277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection.
    Qurishi N; Kreuzberg C; Lüchters G; Effenberger W; Kupfer B; Sauerbruch T; Rockstroh JK; Spengler U
    Lancet; 2003 Nov; 362(9397):1708-13. PubMed ID: 14643119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections.
    Sulkowski MS; Thomas DL; Mehta SH; Chaisson RE; Moore RD
    Hepatology; 2002 Jan; 35(1):182-9. PubMed ID: 11786975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of increased hepatitis C virus (HCV)-specific IgG and soluble CD26 dipeptidyl peptidase IV enzyme activity with hepatotoxicity after highly active antiretroviral therapy in human immunodeficiency virus-HCV-coinfected patients.
    Stone SF; Lee S; Keane NM; Price P; French MA
    J Infect Dis; 2002 Nov; 186(10):1498-502. PubMed ID: 12404169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of genotype 3 hepatitis C coinfection on liver enzyme elevation in HIV-1-positive patients after commencement of a new highly active antiretroviral regimen: results from the EPOKA-MASTER Cohort.
    Torti C; Lapadula G; Puoti M; Casari S; Uccelli MC; Cristini G; Bella D; Pastore G; Ladisa N; Minoli L; Sotgiu G; Caputo SL; Bonora S; Carosi G
    J Acquir Immune Defic Syndr; 2006 Feb; 41(2):180-5. PubMed ID: 16394850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis C virus activation in HIV-infected patients initiating highly active antiretroviral therapy.
    Kim HN; Harrington RD; Shuhart MC; Cook L; Morishima C; Jerome KR; Wang CC
    AIDS Patient Care STDS; 2007 Oct; 21(10):718-23. PubMed ID: 17949270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver enzyme elevation in hepatitis C virus (HCV)-HIV-coinfected patients prior to and after initiating HAART: role of HCV genotypes.
    Maida I; Babudieri S; Selva C; D'Offizi G; Fenu L; Solinas G; Narciso P; Mura MS; Núñez M
    AIDS Res Hum Retroviruses; 2006 Feb; 22(2):139-43. PubMed ID: 16478395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir.
    Sherman KE; Shire NJ; Cernohous P; Rouster SD; Omachi JH; Brun S; Da Silva B
    Clin Infect Dis; 2005 Oct; 41(8):1186-95. PubMed ID: 16163639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy.
    Núñez M; Lana R; Mendoza JL; Martín-Carbonero L; Soriano V
    J Acquir Immune Defic Syndr; 2001 Aug; 27(5):426-31. PubMed ID: 11511818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.